Journal of Clinical Lipidology

Article	Citations
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia	258
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery	157
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor	122
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece	101
Lipoprotein(a) concentrations across a global cross-sectional registry	96
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories	87
Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study	82
Care of youth with lipid disorders: A brief provider survey	77
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis	75
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis	68
Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic Fatty Liver Disease (NAFLD) in Long Term high Fat Diet (HFD) Induced Obesity (DIO) Mouse	67
The Effect of Estrogen and Testosterone on Cholesterol Crystallization	60
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics - Implications for Precision Medicine	55
News from NLA	47
From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss	45
Socioeconomic Disparities in Dyslipidemia and Associated Complications: From the Latest National Database	45
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease	44
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes	44
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report	44
The impact of genetic testing on physician practice in specialized cardiovascular clinics	42
Exciting new developments in clinical lipidology: Updates from the Food and Drug Administration and the American Heart Association	40
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice	40
Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia	38
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection	36
Predictive value of lipoprotein(a) in patients undergoing percutaneous coronary intervention with drug-eluting stent: A meta-analysis	34

Inflammation and cardiometabolic disease in South Asians: The fire and fire tenders	34
Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease	32
Lipoprotein lipase DNA methylation in the adipose tissue of patients with persistent chylomicronemia	32
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study	31
Reanalysis of the impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials	30
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association	28
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the Americ	28
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study	27
From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated	25
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic	25
News from the NLA	23
From the Editors: Update on Diagnosis and Treatment of Familial Hypercholesterolemia	23
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study	23
Efficacy for LDL-C–lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-con	22
Characterization of Inclisiran Use in Real World: Prescription Data from Germany	21
Circumferential periorbital xanthelasma in Leonardo da Vinci’s Head of a Young Woman (1475-1480)	21
Association of sleep duration and quality with small dense low-density lipoprotein cholesterol	21
Country-specific prevalence and clinical relevance of elevated Lp(a) as a risk enhancer in 2 Greek cohorts	21
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy	20
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study	19
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities	18
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)	18
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample	18
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study	18
Severe hypertriglyceridemia induced by everolimus in a lung transplant patient: Case report	17
Table of Contents	17
Unique Case of Management of Severe Hypertriglyceridemia Secondary to Familial Chylomicronemia Syndrome	17
⁎ Incidental Coronary Calcium on Non-Gated CT Scans of the Chest: A Stepwise Approach to Addressing Underreporting and Implementing Deep Learning	16
The Healthy Eating Assessment Tool (HEAT): A Aimplified 10-Point Assessment of CHILD-2 Dietary Compliance for Children with Dyslipidemia	16
Screening for Familial Hypercholesterolemia in the Era of Artificial Intelligence: A Contemporary Narrative Review	15
Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography	15
Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome	15
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands	15
Improvement of severe hypertriglyceridemia in atypical subtype 4 partial lipodystrophy with volanesorsen	15
Health outcomes and survival among patients with severe hypertriglyceridemia after acute pancreatitis	15
Moving beyond clinical risk factors for diagnosis: The necessity of systematic Lp(a) measurement and familial hypercholesterolemia genetic testing	15
Remnant cholesterol and kidney disease progression in type 2 diabetes: A retrospective cohort study	15
Lipoprotein(a) levels and common LPA gene variants in patients with chronic coronary syndrome: genetic determinants and clinical associations	14
Early-pregnancy remnant cholesterol as a modifiable risk factor for gestational diabetes mellitus	14
Predictive value of LDL/HDL cholesterol ratio for new-onset stroke in individuals with cardiovascular–kidney–metabolic syndrome stages 0 to 3: Evidence from the China Health and Retirement Longitudina	14
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study	14
HDL and coronary artery disease	14
A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia	14
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics	13
*An Unsolved Case: FH or Sitosterolemia?	13
†Safety and Efficacy of Bempedoic Acid in Patients with Hypertension	13
Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency	13
Management of Atherogenic Dyslipidemia in a Patient with LDL Discordance	13
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH)	13
Editorial Board	13

Disruption of HDL antioxidant properties in children and adolescents with obesity	13
Marked Hypoleptinemia precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy	13
Implementation strategies to optimize the use of nonstatin add-on lipid-lowering therapies in individuals with dyslipidemia: A systematic review	12
From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII	12
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population	12
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022	12
Familial hypercholesterolemia concealed by a protein-truncating variant of PCSK9	12
Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes	12
Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers	12
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins	12
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome	12
The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study	12
Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease	12
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic	12
Corrigendum to “Association between the cardiometabolic index and mortality risk in US adults: Data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018” [Journal of Clinical L	11
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis	11
Lipoprotein(a) and TAVR outcomes: Methodological challenges and clinical implications	11
Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease	11
Association of cumulative low-density lipoprotein cholesterol exposure with vascular function	11
Novel APOB variant causes familial hypercholesterolemia in multiple unrelated families	11
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study	11
Enzyme replacement therapy in cholesteryl ester storage disease: A case report on lysosomal acid lipase deficiency management	11
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL	11
Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size	11
The 2025 AACE Dyslipidemia Guidelines – Cost concerns over evidence and missing the target?	11
Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia	10
Response to the letter regarding “Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function”	10
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases	10
Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?	10
Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome: Data from an expanded access program	10
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice	10
Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients	10
Overcoming the real and imagined barriers to cholesterol screening in pediatrics	10
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.	10
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography	9
Community pharmacist impact of addressing statin use in patients with diabetes	9
Effects of evinacumab on high-density lipoprotein function in patients with homozygous familial hypercholesterolemia	9
An Indian adapted Mediterranean diet: A feasibility study	9
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis	9
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease	9
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury	9
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia	9
Is Tangier disease a rare cause of premature ovarian insufficiency?: A case report	9
Concordance between LDL-C estimated by various formulas and directly measured LDL-C	9
Hourly 4-minute walking breaks from sitting following aerobic exercise reduce postprandial non-HDL cholesterol in healthy young adults: A randomized crossover trial	9
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis	9
Enhancing lipoprotein(a) association studies: A complementary approach to principal component analysis	9
Why Are Patients Presenting with STEMI Already on Statin Not Treated with Additional Aggressive Lipid-lowering Agents?	9
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia	9
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre	9
Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials	8
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk	8
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	8
Functional profiling of LDLR variants: Important evidence for variant classification	8
Multidimensional lipid phenotyping for stratification of residual cardiovascular risk: A focus on fatty acid balance	8
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study	8
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction	8
Bempedoic acid vs ezetimibe added to statin therapy: Cardiovascular outcomes in the real-world—The BEYOND-REAL Study	8
Plasma-based low-grade inflammation and endothelial dysfunction explain a small but significant proportion of the association between the n-3 polyunsaturated fatty acids and cardiovascular diseases: T	8
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America	8
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones	8
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD	7
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients	7
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia	7
CAC Scoring as an Index for Subclinical Carotid Atherosclerosis	7
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?	7
Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects	7
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report	7
Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agen	7
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome	7
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.	7
Table of Contents	7
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction	7
Heterogeneous nature of severe hypertriglyceridemia in childhood	6
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized control	6
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report	6
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)	6
In memoriam: A tribute to Dr Scott M. Grundy	6
Population enrichment of ABCG5/ABCG8 variants in Qatar and genetic estimates of sitosterolemia burden	6
Does apolipoprotein B matter in the care of familial hypercholesterolemia?	6

Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye	6
Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterole	6
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia	6
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data	6
Cardiovascular disease and cholesterol lowering therapy in women and men with molecularly defined heterozygous familial hypercholesterolemia from Brazil	6
Sex differences in inflammatory biomarkers during long-term evolocumab therapy	6
Lipoprotein(a) at the crossroads of inflammation and atherosclerosis in rheumatoid arthritis: A narrative review	6
Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases—Insights from a preventive cardio-rheuma clinic	6
A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis	6
Omega-3 supplementation and Lp-PLA2: Attention to nonindependent comparisons in meta-analysis	6
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM	6
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates	6
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments	6
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia	6
Association between very high HDL-C levels and mortality: A systematic review and meta-analysis	6
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review	6
Associations of lipid-lowering drugs with cardiovascular-kidney-metabolic syndrome: A drug-target Mendelian randomization study	6
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up	5
†Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome	5
Effect of Dexamethasone on Modulating Lp(a) Levels in COVID-19 Pneumonia	5
What's next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion	5
Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function	5
From the Editors: New 2026 guideline for management of dyslipidemia	5
Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial	5
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention	5
Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States	5
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults	5
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk	5
*A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy.	5
From the editor: A compendium of lipidology progress	5
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma	5
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia	5
Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial	5
Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome	5
Dedicated training in obesity management: A pathway to better physician practice	5
From the editor: Lipidology resurgent as the pandemic wanes	5
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions	5
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors	5
Comprehensive analysis of Chinese patients with non-LPL familial chylomicronemia syndrome: Genetic variants, dietary interventions, and clinical insights	5
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022	5
^Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia	5
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci	5
Triglyceride-glucose index and triglyceride-glucose index-related markers for identifying metabolic syndrome in Saudi Arabia	5
Impact of omega-3 supplementation on lipoprotein-associated phospholipase A2 mass and activity: A systematic review and meta-analysis of randomized controlled trials	5
High lipoprotein(a) and stroke: Association with large artery and intracranial atherosclerosis—A retrospective study	5
Lipoprotein(a): Mirroring Familial Hypercholesterolemia	5
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia	5
Equitable Access to Screening and Lipid-Lowering Therapies in a Large Academic Center after Educational Interventions	5
Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial	5
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results	5
Diagnosis and Management of Familial Dysbetalipoproteinemia in a Patient with Apo E2/E2 Genotype	4
Severe Hypertriglyceridemia as a Cause of Arterial Thrombosis with Peripheral Embolic Complications.	4
Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial	4
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table	4
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration	4
The analysis of the breakpoint of large rearrangements of LDLR gene in a Taiwanese cohort of patients with familial hypercholesterolemia	4
Neurodegeneration in familial chylomicronemia syndrome	4
Lipedema is not obesity—A call for clinical clarity	4
Pharmacotherapy development and trends in lipidology: An expert discussion	4
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice	4
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer	4
CME Activity Highlights the Improvement in Clinician's Knowledge and Competence about Treatment Choices for LDL-C Lowering Post-MI	4
Pegylated-Asparaginase Induced Severe Hypertriglyceridemia in an Adult with Acute B-cell Lymphoblastic Leukemia	4
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis	4
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence	4
New directions in childhood obesity treatment – A path forward or wishful thinking?	4
Symptom and comorbidity burden in familial chylomicronemia syndrome: Impact on quality of life	4
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis	4
Discontinuation of lipid-modifying agents and failure to achieve target LDL cholesterol levels across cardiovascular risk groups	4
† Higher Cardiovascular Event Rates for High-Risk Americans Who Did Not Meet 2018 Multidisciplinary Guideline on the Management of Blood Cholesterol Thresholds	4
Pancreatitis in severe hypertriglyceridemia is a failure of temporal lipoprotein buffering: Not a problem of static lipid burden	4
Prevalence, patterns, and geographical distribution of cardiometabolic multimorbidity and its association with unhealthy behaviors among Chinese adults: Evidence from the China National Nutrition Heal	4
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?	4
Healthcare costs among acute pancreatitis patients with severe hypertriglyceridemia	4
Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis	4
Unveiling Compound Heterozygous Familial Hypercholesterolemia	4
Positive association between apolipoprotein B and colorectal cancer risk: Findings from a 14-year follow-up cohort study and Mendelian randomization analyses	4
Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study	4
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy	4
Association of LDL-C between parents and younger offspring: A cross-sectional study using the Korea National Health and Nutrition Examination Survey	4
Editorial Board	4
Oral semaglutide and reduction in major adverse cardiovascular events	4
The Food Compass Score is Negatively Related to the Activity of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Healthy Adults.	4
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipid	4
Treatment Target Achievement in Patients with Familial Hypercholesterolemia: A Real-World Descriptive Study	4
Reframing lipoprotein(a): From physician knowledge gaps to a multidisciplinary translational gap	4
Precision approach in apoA-I infusion trials: When CSL112 may actually work	4
A qualitative study to explore the patient experience of hypertriglyceridemia-related acute pancreatitis	3
Adult onset very long chain acyl-CoA dehydrogenase deficiency: A case report	3
Statin therapy for primary prevention in women: What is the role for coronary artery calcium?	3
Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome	3
Corrigendum to Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association [Journal of Clinical Lipidology Volume 13, Issue	3
Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia	3
Case Report - Lysosomal Acid Lipase Deficiency - A Rare Cardiometabolic Disease and a NAFLD Mimic	3
Development of a Clinical Diagnostic Score for Familial Chylomicronemia Syndrome (FCS)	3